Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 80
Updated:6/28/2018
Start Date:August 2015
End Date:December 2019
Contact:Daniel Gareau, PhD, MCR
Email:dgareau@rockefeller.edu
Phone:2123277983

Use our guide to learn which trials are right for you!

Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

The purpose of this study is to calculate the sensitivity and specificity of a novel imaging
device and associated software algorithm in detecting early stage melanoma versus nevi of the
skin. The instrument, which was invented by the PI, for the purposes of this study, will be
loaned to three external (to Rockefeller) institutions and used on patients who are scheduled
for biopsy of pigmented lesions. The purpose of correlating the output screening result of
the novel device and the output diagnosis of the gold standard histology analysis procedure
is so that these two diagnoses can be compared to generate the number of true positives, true
negatives, false positives and false negatives for the novel device. The purpose of
disseminating the device to the external institutions is to achieve the appropriate power
such that the specificity can be evaluated at 99% sensitivity. The rationale for the power
needed in the study is that in order to be clinically useful, the device needs to be
extremely sensitive (i.e. 99%) because false negative diagnosis is a dangerous situation,
leading to potential progression of melanoma, the most deadly form of skin cancer.

The purpose of this study is to calculate the sensitivity and specificity of a novel imaging
device and associated software algorithm in detecting early stage melanoma versus nevi of the
skin. The instrument, which was invented by the PI, for the purposes of this study, will be
loaned to three external (to Rockefeller) institutions and used on patients who are scheduled
for biopsy of pigmented lesions. The purpose of correlating the output screening result of
the novel device and the output diagnosis of the gold standard histology analysis procedure
is so that these two diagnoses can be compared to generate the number of true positives, true
negatives, false positives and false negatives for the novel device. The purpose of
disseminating the device to the external institutions is to achieve the appropriate power
such that the specificity can be evaluated at 99% sensitivity. The rationale for the power
needed in the study is that in order to be clinically useful, the device needs to be
extremely sensitive (i.e. 99%) because false negative diagnosis is a dangerous situation,
leading to potential progression of melanoma, the most deadly form of skin cancer.

The scientific hypothesis is that the diagnostic mechanism for superficial melanoma is the
light tissue interaction that occurs between the blue shifted wavelengths (i.e. blue light,
ultra violet light) and the superficial epidermis while the mechanism for diagnosis of deeper
melanoma (i.e. Breslow depth >0.5mm) is the light/tissue interaction that occurs between the
red shifted light (i.e. red light, infrared light) and the portion of the pigmented lesion
that lies within the dermis. These hypotheses were fueled by initial observations that the
diagnostic sensitivity and specificity were wavelength dependent in a study that looked at
only the red, green and blue wavelengths as available in traditional digital dermoscopy
imaging. The initial finding was that of the multiple features analyzed, more features were
statistically significant diagnostics in the blue channel but there were (a relative
minority) other features that fared better in the red channel. It is hypothesized that the
diagnostic features that did better in the red channel were features of deep melanin while
the superficial regions, which should theoretically be atypical in ALL melanomas, were
evident in the quantitative endpoint metrics generated from the blue channel.

Inclusion Criteria:

- Participant has normal appearing skin and a suspicious pigmented lesion.

Exclusion Criteria:

- Lesion near the eyes (due to safety)

- Inaccessibility to lesion related to device: ears, toes, fingers, nailbeds, ankles,
elbows, genitals

- Self-reported history of photosensitivity

- Self-reported history of vitiligo and/or other sun sensitive disease
We found this trial at
5
sites
Portland, Oregon 97227
Principal Investigator: Sancy Leachman, MD, PhD
?
mi
from
Portland, OR
Click here to add this to my saved trials
Irvine, California 92612
Principal Investigator: Kenneth Linden, MD
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Orange, California 92868
Principal Investigator: Kenneth Linden, MD
?
mi
from
Orange, CA
Click here to add this to my saved trials
201 Northwest 82nd Avenue
Plantation, Florida 33324
Principal Investigator: Harold Rabinovitz, MD
Phone: 954-473-6750
?
mi
from
Plantation, FL
Click here to add this to my saved trials
1 Shields Ave
Sacramento, California 95616
(530) 752-1011
University of California-Davis As we begin our second century, UC Davis is poised to become...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials